(1)

All pharmacologically active substances used in the Community in veterinary medicinal products intended for food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.

(2)

Following examination of an application for the establishment of maximum residue limits for firocoxib in Equidae and in order to allow for the completion of minor scientific validation of studies, it is considered appropriate to include firocoxib in Annex III to Regulation (EEC) No 2377/90 for Equidae species.

(3)

The substance triclabendazole is included in Annex I to Regulation (EEC) No 2377/90 for bovine and ovine for muscle, kidney and liver, excluding animals producing milk for human consumption. Following examination of an application for the modification of those maximum residue limits, it is considered appropriate to include triclabendazole in that Annex for all ruminants for muscle, fat, liver and kidney, excluding animals producing milk for human consumption amending the maximum residue limits values.

(4)

Regulation (EEC) No 2377/90 should therefore be amended accordingly.

(5)

An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any necessary adjustment in the light of this Regulation to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (2).

(6)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,